

Analyst

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1
2
3
4 1 **Relative quantification of amine-containing metabolites**
5
6
7 2 **using isobaric *N,N*-dimethyl-leucine (DiLeu) reagents via**
8
9
10
11 3 **LC-ESI-MS/MS and CE-ESI-MS/MS**
12
13

14
15 4 Ling Hao^a, Xuefei Zhong^a, Tyler Greer^b, Hui Ye^c, Lingjun Li^{*ab}
16

17
18 5 ^aSchool of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, WI,
19 6 53705, USA

20
21 7 ^bDepartment of Chemistry, University of Wisconsin-Madison, 1101 University Avenue,
22 8 Madison, WI 53706, USA

23
24 9 ^cChina Pharmaceutical University, Nanjing, 210009, China
25
26
27 10
28
29
30 11
31
32
33 12
34
35
36 13
37
38
39 14
40
41
42 15
43
44
45 16
46
47

48 17 *Corresponding author
49

50
51 18 Tel.: +1 (608) 265-8491
52

53
54 19 Fax: +1 (608) 262-5345
55

56
57 20 E-mail: lingjun.li@wisc.edu
58
59
60

1
2
3 21 **Abstract**
4
5

6 22 Tandem mass spectrometry (MS/MS)-based relative quantification by isobaric labeling is a
7
8
9 23 useful technique to compare different metabolic expression levels in biological systems. For the
10
11 24 first time, we have labeled primary and secondary amine-containing small molecules using 4-plex
12
13 25 isobaric *N,N*-dimethyl-leucine (DiLeu) to perform relative quantification. Good labeling
14
15 26 efficiency and quantification accuracy were demonstrated with a mixture of 12 metabolite
16
17
18 27 standards including amino acids and small molecule neurotransmitters. Labeling amine-containing
19
20 28 metabolites with DiLeu reagents also enabled the separation of polar metabolites by nanoRPLC
21
22
23 29 and improved the detection sensitivity by CE-ESI-MS. The 4-plex DiLeu labeling technique
24
25 30 combined with LC-MS/MS and CE-MS/MS platforms were applied to profile and quantify amine-
26
27
28 31 containing metabolites in mouse urine. The variability of concentrations of identified metabolites
29
30 32 in urine samples from different mouse individuals was illustrated by the ratios of reporter ion
31
32 33 intensities acquired from online data-dependent analysis.
33
34
35
36 34
37
38 35
39
40
41 36
42
43
44
45 37
46
47
48 38
49
50
51 39
52
53
54 40
55
56
57 41
58
59
60

42 Introduction

43 Endogenous metabolites represent a diverse group of small molecules that can directly reflect
44 enzymatic activities in the biological system. Specifically, amine-containing small molecules like
45 amino acids and neurotransmitters serve as the basic building blocks and key regulators of
46 biological organisms.¹ The dysregulation of amine metabolites in biofluids has been studied for a
47 number of diseases, such as Parkinson's disease, kidney cancer, and Alzheimer's disease.¹⁻⁷
48 Serotonin plays important roles in the biochemistry of memory, depression, and anxiety disorder;
49 the decline of dopamine levels has been shown to be directly related to Parkinson's disease;⁶ γ -
50 Aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the central nervous system.⁸
51 Monitoring the expression levels of amine containing metabolites using hyphenated mass
52 spectrometric techniques is essential to study the complex processes of life. However, the detection
53 and separation of amine-containing metabolites with MS-based platforms are still challenging
54 because of their low abundance, high polarity and poor ionization efficiency. Several strategies
55 involve chemical derivatization of metabolites prior to C18 reversed phase (RP) LC-MS and the
56 use of other LC-MS platforms such as hydrophilic interaction chromatography (HILIC)-MS^{9, 10}
57 and ion-pairing reversed phase chromatography-MS.^{11, 12} Additionally, capillary zone
58 electrophoresis (CZE) separates free metabolites based on charge-to-size ratio and has been
59 coupled to MS for metabolomics studies.¹³⁻¹⁸

60 Mass spectrometry-based quantification is another key component in amine metabolite analysis.
61 For absolute quantification, an isotopic analogue of the analyte (²H- or ¹³C- analogues) is spiked
62 into samples as an internal standard.^{19, 20} However, the use of isotopic internal standard is usually
63 expensive and only suitable for some targeted analyses because of the unavailability of many
64 isotopic metabolite standards. Therefore, relative quantification through label-free or chemical

1
2
3 65 derivatization approaches offers an alternative and often more useful way to compare different
4
5 66 biological states. Determining the relative abundance of metabolites with MS-based techniques
6
7
8 67 has been successfully applied to discover potential metabolic biomarkers of various human
9
10 68 diseases.²¹⁻²⁴
11
12

13 69 Stable isotope labeling is an accurate and high-throughput methodology for relative
14
15 70 quantification. It has been widely used for quantitative proteomics and peptidomics and also
16
17
18 71 adopted to quantify small molecules in recent years.^{25,26} Stable isotope labeling can be categorized
19
20 72 into two groups, mass-difference labeling and isobaric labeling. Mass-difference labeling, such as
21
22 73 ¹²C-/¹³C-methyl acetimidate,²⁷ dansylation,^{28, 29} and formaldehyde dimethylation,³⁰ introduces a
23
24 74 fixed mass difference for the same metabolite in a MS spectrum. Relative quantification is
25
26 75 achieved by comparing extracted ion chromatogram peak areas of the heavy and light isotopic
27
28 76 forms of the same metabolite. Isobaric labeling with TMT^{31, 32} and iTRAQ^{33, 34} tags has also been
29
30 77 employed for the quantification of primary and secondary amine-containing metabolites. Most
31
32 78 recently, Murphy et al.³² employed 10-plex TMT tags to measure amino acids in parallel with
33
34 79 cellular proteins from cancer cells. Generally, isobaric labeling reagents are comprised of an
35
36 80 isotopically-coded reporter, a balance group, and an amine reactive group. The balanced structure
37
38 81 of each label shifts precursor mass values by the same amount upon chemical incorporation. Upon
39
40 82 MS/MS fragmentation, the reporter is cleaved from the balance group, and each labeled sample
41
42 83 produces a unique reporter ion whose intensity represents the relative abundance of the metabolite
43
44 84 from the original sample.
45
46
47
48
49
50

51 85 To enrich and advance MS-based quantification with isobaric labeling, the multiplex *N,N*-
52
53 86 dimethyl leucines (DiLeu) reagent was designed and synthesized in our lab with several
54
55 87 advantages in terms of cost, labeling efficiency, quantitative accuracy, and fragmentation. 4-plex
56
57
58
59
60

1
2
3 88 DiLeu tags (Scheme 1A) have been previously developed and utilized for the relative
4
5 89 quantification of proteins and peptides³⁵⁻³⁸ with excellent accuracy and reproducibility. Unlike
6
7
8 90 mass-difference reagents, isobaric DiLeu tags do not increase mass spectral complexity, as the
9
10 91 same compound labeled with isobaric DiLeu tags produces a single peak in the MS scan with a
11
12 92 mass increase of 145.14 Da. This is especially important for complex biological samples
13
14 93 containing a variety of different compounds. Relative quantification can be achieved by comparing
15
16 94 the intensities of reporter ions (m/z 115.1, 116.1, 117.1, 118.1) in MS/MS fragmentation. DiLeu
17
18 95 reagents also showed increased reporter ion signal over iTRAQ.³⁶ In addition, because of the
19
20 96 relatively simple synthetic route, the reagents cost for synthesizing a set of 4-plex DiLeu tags (1mg)
21
22 97 for one quantification experiment is less than \$5.00, which is a significant monetary decrease
23
24 98 compared to more expensive commercial isobaric tags like TMT (6-plex: \$500) and iTRAQ (4-
25
26 99 plex: \$275).

31
32 100 Herein we describe the first application of the 4-plex DiLeu tags to relative quantification of
33
34 101 amine-containing metabolites (Scheme 1B). We demonstrated good separation and quantification
35
36 102 of DiLeu labeled metabolites using both nanoLC-ESI-MS/MS and CE-ESI-MS/MS platforms. We
37
38 103 further employed the MS-based DiLeu labeling strategy for the identification and relative
39
40 104 quantification of primary and secondary amine-containing metabolites in mouse urine samples.
41
42
43
44

105

106 **Experimental**

107 **Chemicals and Reagents**

50
51 108 Optima LC/MS grade acetonitrile, methanol and water, *N,N*-dimethylformamide (DMF), and 4-
52
53 109 (4, 6-dimethoxy-1, 3, 5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) were purchased
54
55
56
57
58
59
60

1
2
3 110 from Fisher Scientific (Fair Lawn, NJ). N-methylmorpholine (NMM) was purchased from TCI
4
5 111 America (Tokyo, Japan). 12 Metabolite standards (histidine, valine, tyrosine, leucine, lysine,
6
7
8 112 phenylalanine, tryptophan, alanine, serotonin, dopamine, γ -aminobutyric acid, and
9
10 113 norepinephrine), 3-aminoquinoline, and triethylammonium bicarbonate (TEAB) was purchased
11
12 114 from Sigma (St. Louis, MO). Formic acid (FA) ($\geq 98\%$) was obtained from Fluka (Büchs,
13
14
15 115 Switzerland). C18 and OMIX SCX Ziptips were purchased from Millipore and Agilent,
16
17 116 respectively. Deionized water (18.2 M Ω ·cm) was prepared with a Milli-Q Millipore system
18
19
20 117 (Billerica, MA).

21 22 23 118 ***N,N*-dimethylated leucine (DiLeu) synthesis and activation**

24
25
26 119 4-plex DiLeu reagent synthesis was previously described by Xiang et al.³⁶ Dry DiLeu labels were
27
28 120 stored at -20 °C until usage. DiLeu reagents were activated to DiLeu triazine ester immediately
29
30 121 before metabolite labeling. Each 1 mg dried DiLeu label was activated by mixing with 1.86 mg
31
32 122 DMTMM, 0.74 μ L NMM and 50 μ L DMF, and then vortexed at room temperature for 1h. After
33
34 123 activation, each isobaric DiLeu triazine ester was used separately for labeling.
35
36
37

38 124 **Labeling metabolite standards**

39
40
41 125 Stock solution containing 1mM of each metabolite standard was prepared and stored at -20 °C
42
43 126 before use. 10 μ L of diluted stock solution containing 10 μ M of each metabolite was dried with a
44
45 127 SC 110 SpeedVac concentrator (Thermo Electron Corporation, West Palm Beach, FL), redissolved
46
47 128 in 0.5M TEAB solution, and divided into four aliquots with molar ratios of 1:1:1:1 or 1:2:5:10.
48
49 129 Each aliquot was mixed with activated DiLeu triazine ester 115, 116, 117, or 118, respectively.
50
51 130 For each labeling reaction, activated DiLeu reagents and metabolites mixture were reacted at a
52
53 131 molar ratio of 20:1 to ensure efficient and complete labeling under room temperature for 2 h with
54
55
56
57
58
59
60

1
2
3 132 shaking. The reaction was then quenched by adding 100 μL of water and shaking for 30 min.
4
5 133 Subsequently, labeled samples were each dried *in vacuo* and combined at equal ratios. OMIX SCX
6
7
8 134 Ziptips (10 μL) were used to remove residual labeling chemicals, with 0.1% FA in H_2O used as
9
10 135 the reconstitution and washing solutions, and 5% $\text{NH}_3\cdot\text{H}_2\text{O}$ in 30% MeOH as elution solution. The
11
12 136 eluate was concentrated to dryness and stored at $-20\text{ }^\circ\text{C}$ until analysis.

16 137 **Labeling urinary metabolites**

17
18
19 138 Urine samples from individual mice were collected in metabolic cages and stored at $-80\text{ }^\circ\text{C}$ until
20
21 139 further usage. An aliquot of 60 μL from each mouse urine sample was transferred to a 0.6 mL
22
23 140 eppendorf tube and centrifuged at 10000g for 10 min to remove cellular debris. 50 μL of the
24
25 141 supernatant was transferred into a new tube and diluted with 100 μL of water. Metabolite fractions
26
27 142 of urine were obtained by using 3 kDa molecular weight cut-off filters (Millipore Amicon Ultra)
28
29 143 to remove urinary proteins. The flow-through fraction was collected and concentrated to dryness.
30
31 144 Dried urinary metabolites from four mice were labeled with 4-plex DiLeu reagents separately,
32
33 145 combined at equal ratios, and cleaned up with SCX Ziptips using the same procedures described
34
35 146 above. Labeled mouse urine sample was dried down and reconstituted in 0.1% FA in H_2O for LC-
36
37 147 MS analysis or 0.1% FA in 50% MeOH for CE-MS analysis.
38
39
40
41
42

43 148 **Direct infusion ESI-MS and ESI-MS/MS**

44
45
46 149 Mixtures of 12 DiLeu labeled metabolite standards (1:1:1:1 ratio and 1:5:2:10 ratio) were re-
47
48 150 dissolved in 100 μL of 0.1% FA in 50% acetonitrile (ACN) solution, and directly infused into a
49
50 151 Waters Synapt-G2 Q-TOF mass spectrometer (Waters Corp., Milford, MA) with a flow rate of 1
51
52 152 $\mu\text{L}/\text{min}$. Electrospray emitter tips were prepared with a Sutter P-2000 laser capillary puller
53
54 153 (Novator, CA, USA) from 75 μm i.d., 360 μm o.d. capillary tubing (Polymicro Technologies,
55
56
57
58
59
60

1
2
3 154 Phoenix, AZ, USA). The capillary voltage was set to 2.7 kV, sampling cone voltage to 20 V,
4
5
6 155 extraction cone voltage to 4 V, source temperature to 70 °C, and cone gas to 30. Data were acquired
7
8 156 in positive ESI, resolution mode, with a scan rate of 1 s/scan. MS and MS² analysis were acquired
9
10 157 from m/z 80-500 and m/z 100-500, respectively. MS² analysis of each labeled metabolite was
11
12 158 achieved by collision induced activation (CID) using argon as the collision gas with a collision
13
14 159 energy of 30 eV and a precursor isolation window of ~3 Th. Acquired data were analyzed with
15
16 160 MassLynx 4.1 software. A total of 118 MS/MS scans of each labeled compound were combined
17
18 161 for the measurement of reporter ion intensity.
19
20
21
22

23 162 **Reversed phase nanoLC-ESI-MS/MS**

24
25
26 163 Reversed phase nanoLC-ESI-MS/MS analyses of labeled metabolite standards and mouse urine
27
28 164 samples were conducted using a Waters nanoAcquity ultra-performance liquid chromatography
29
30 165 (UPLC) system coupled online to a Waters Synapt-G2 Q-TOF mass spectrometer. Mobile phase
31
32 166 A was 0.1% FA in H₂O and mobile phase B was 0.1% FA in ACN. The sample was dissolved in
33
34 167 10 μL of 0.1% FA in H₂O, and 3 μL was loaded onto a sample loop connected to a homemade C18
35
36 168 column (75.1 μm × 150mm, 1.7 μm, 100 Å). The 35 min binary gradient at a flow rate of 0.35
37
38 169 μL/min was set as follows: 0- 10 min, 0- 40% solvent B; 10- 30 min, 40%- 85% solvent B; 31-
39
40 170 35min, 97% solvent B. Full MS scan was acquired with a mass range of 100 ~ 800 m/z and a scan
41
42 171 rate of 0.5 s/scan. In the selected reaction monitoring (SRM) acquisition, 12 SRM channels were
43
44 172 developed for 12 precursor masses of DiLeu labeled metabolites. The collision energy was 30 eV
45
46 173 and the cycle time was 0.1s for each SRM channel. In the top 5 data dependent acquisition, a
47
48 174 survey scan was followed by three MS² scans of each precursor ion within the top 5 intensities.
49
50
51
52
53 175 The collision energy was 30 eV and precursor isolation window was ~3 Th. Dynamic exclusion
54
55
56
57
58
59
60

1
2
3 176 was set to 60 s and 15 masses from interfering background peaks were programmed in the
4
5
6 177 precursor exclusion list.
7

8 9 178 **CE-ESI-MS/MS**

10
11
12 179 An HP Agilent G1600AX 3D CE system was coupled with the Synapt-G2 mass spectrometer
13
14 180 using a flow-through microvial CE-ESI-MS interface developed by Maxwell et al.³⁹ The sample
15
16 181 dissolved in 0.2% FA in 50% MeOH was injected into the column by applying 50 mbar for 20 s
17
18 182 at the inlet end. 0.2% FA in 50% MeOH was used as the background electrolyte and modifier
19
20
21 183 solution. During separation, 30 kV was applied at the inlet of the 80 cm long, 50 μ m ID bare fused-
22
23 184 silica capillary column, and the modifier solution was infused at 0.3 μ L/min by a syringe pump.
24
25
26 185 Between runs, the capillary was flushed with the background electrolyte solution for 5 min. Full
27
28 186 MS and top 5 data dependent acquisition were conducted in positive mode with the same
29
30
31 187 parameters as those in nanoLC-MS/MS.
32

33
34 188

35 36 37 189 **Results and discussion**

38 39 40 190 **Labeling efficacy of metabolites by DiLeu reagents**

41
42
43 191 Although the workflow of DiLeu labeling has already been established for peptide analysis in a
44
45 192 previous study³⁶, specific conditions for metabolite labeling need to be further optimized. The
46
47 193 labeling efficiency was evaluated by directly infusing DiLeu labeled metabolite standards onto a
48
49
50 194 Synapt G2 Q-TOF mass spectrometer. DiLeu activation for one hour and labeling for two hours
51
52 195 were found to be optimal conditions for metabolite labeling. The spectral comparison between
53
54 196 labeled and unlabeled metabolites is shown in Fig. 1 (A, B). Metabolite labeled by 4-plex DiLeu
55
56
57 197 reagents showed a single peak in the MS spectrum with a mass shift of 145.14 Da compared to the
58
59
60

1
2
3 198 unlabeled counterpart. Because lysine contains another primary amine group on its side chain, the
4
5 199 mass shift of a completely labeled Lysine is 290.28 Da. As illustrated in Fig. 1 (A), lysine only
6
7
8 200 showed a completely labeled peak (m/z 437.4). Unlabeled metabolite standard peaks were not
9
10 201 observed in the DiLeu labeled spectrum, indicating good labeling efficiency under optimized
11
12 202 conditions. In order to remove salts, excessive DiLeu reagents, and reaction by-products in the
13
14 203 reaction mixture while maintaining high recovery of labeled metabolites, C18 and SCX Ziptips
15
16 204 were employed and their clean-up performances were compared. OMIX SCX Ziptips, with an
17
18 205 eluting solution of 5% $\text{NH}_3 \cdot \text{H}_2\text{O}$ in 30% MeOH, were selected as the purification method prior to
19
20 206 instrumental analysis.
21
22
23
24

25 207 **Tandem mass spectrometry based relative quantification of isobarically labeled metabolite** 26 27 **standards** 28 29

30
31 209 In order to examine the accuracy and reproducibility of relative quantification, two sets of
32
33 210 metabolite standard mixtures with known concentration ratios (1:1:1:1 and 1:5:2:10) were
34
35 211 differentially labeled by 4-plex DiLeu and pooled together with equal ratios. Combined labeled
36
37 212 metabolites were purified with SCX Ziptips and analyzed by direct infusion ESI-MS/MS analysis.
38
39 213 The precursor ion of each labeled compound was isolated by the quadrupole and subjected to CID
40
41 214 fragmentation with 30 eV collision energy. In addition to reporter ions, a neutral loss of H_2O can
42
43 215 be observed in MS/MS spectra of some labeled metabolites. An example of a MS/MS spectrum of
44
45 216 DiLeu labeled norepinephrine is shown in Fig. 1 (C). Relative quantification of the metabolite was
46
47 217 achieved by calculating the intensity ratios of DiLeu reporter ions (m/z 115.1, 116.1, 117.1, 118.1)
48
49 218 produced in MS/MS fragmentation. Because of the natural ^{13}C isotope and the isotopic impurities
50
51 219 from synthesis reagents, the intensities of DiLeu reporter ions which are approximately 1Da apart
52
53 220 from each other can be interfered by isotopic impurities. Raw reporter ion intensities must be
54
55
56
57
58
59
60

1
2
3 221 corrected to account for the losses to, and gains from, other reporter ions. Purity-correction was
4
5 222 performed in an excel spreadsheet to correct reporter ion intensities obtained from MS/MS
6
7
8 223 spectra.^{38,40} Correction factors and equations can be found in Fig. S1 (See supporting information).
9
10 224 The ratios of reporter ion intensities were then calculated from the corrected values for each
11
12 225 metabolite. The results were summarized in the box plots in Fig. 2. The median ratios measured
13
14 226 among 12 metabolites were 1:0.92:0.89:0.88 with a theoretical ratio of 1:1:1:1, and
15
16 227 1:4.83:1.87:9.59 with a theoretical ratio of 1:5:2:10. Both groups showed satisfactory accuracy
17
18 228 (within 12% error) for relative quantification. Linear dynamic range of at least one order of
19
20 229 magnitude was also confirmed with the 1:5:2:10 ratio group. Linear regression of experimental
21
22 230 ratios to the theoretical 1:5:2:10 ratio of each labeled metabolite showed satisfactory slope (close
23
24 231 to 1) and linear correlation (Table 1). Examples of linear regression of labeled metabolites can be
25
26 232 found in Fig. S2 (See supporting information).
27
28
29
30
31

32 233 **RPLC-ESI-MS and CE-ESI-MS analysis of DiLeu labeled metabolite standards**

34
35 234 Studies have shown that polar metabolites usually elute within the first few minutes on a regular
36
37 235 C18 RPLC column.⁴¹⁻⁴³ Furthermore, nanoRPLC-MS systems detect most polar metabolites
38
39 236 infrequently if at all. Poorly retained metabolites are most likely washed away or highly diluted
40
41 237 during the trapping process. DiLeu labeling of metabolites enables the separation of polar
42
43 238 metabolites by nanoRPLC due to the increased hydrophobicity. Extracted ion chromatograms of
44
45 239 12 DiLeu labeled metabolite standards using nanoRPLC is shown in Fig. 3. Unlabeled metabolites
46
47 240 do not retain on the nanoRPLC column, barely showing any signal. Conversely, after DiLeu
48
49 241 labeling, 12 metabolite standards were well separated with greatly increased sensitivity.
50
51
52
53
54

55 242 DiLeu labeling of metabolites was also evaluated with CE-MS, which is routinely utilized to
56
57 243 separate charged and polar molecules as an alternative platform to LC-MS. A flow-through
58
59
60

1
2
3 244 microvial CE-ESI-MS interface, where CE effluent combined with modifier flow inside the
4
5 245 microvial at the end of the separation column,²⁹ was utilized to build a stable and sensitive CE-MS
6
7
8 246 platform.^{39, 44} DiLeu labeling of metabolites significantly enhanced their signals in CE-MS
9
10
11 247 analysis with a fold change larger than 10 for most metabolite standards. The extracted ion
12
13 248 electropherograms of label free and Dileu labeled 12 metabolite standards are compared in Fig. 4.
14
15 249 The signal intensity was increased by more than 200 fold for alanine after labeling with DiLeu.
16
17 250 Improved detection sensitivity by DiLeu labeling was due to the increased hydrophobicity and
18
19 251 electrospray ionization efficiency. The DiLeu tag most likely facilitates the migration of
20
21 252 metabolites to the surface of droplets and improves their ability to acquire a proton before or during
22
23 253 escape from the surface of electrospray droplets,⁴⁵ increasing the electrospray ionization efficiency
24
25 254 of amine-containing metabolites. In addition, the migration time and order of metabolites during
26
27 255 the CE separation were also changed by DiLeu labeling due to the increased pKa and molecular
28
29 256 size. Free metabolites were separated between 13.9 min to 22.2 min, while labeled metabolites
30
31 257 eluted from 14.2 min to 18.9 min. The compromised CE separation efficiency might be a potential
32
33 258 pitfall for separating complex biological samples since DiLeu labeling reduced the structural
34
35 259 differences among different metabolites. To address this limitation, an orthogonal separation
36
37 260 technique such as ion mobility, which can separate gas phase ions based on charge and collision
38
39 261 cross section (CCS), can be integrated into our current separation platform.³⁸ Additionally,
40
41 262 interfering background signals in the low mass range (m/z 50-200) usually complicate MS-based
42
43 263 metabolomics studies since metabolite intensities can be suppressed by background signals,
44
45 264 especially for low abundance analytes. DiLeu labeling helps alleviate this issue by shifting
46
47 265 metabolite masses into a higher m/z range with fewer interference peaks.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 266 The reproducibility, linearity and sensitivity of the labeling approach for 12 metabolite standards
4
5
6 267 were tested in comparison with the label free method (Table 1). Limits of detection (LOD) of 12
7
8 268 unlabeled metabolites ranged from 0.13 to 1.24 $\mu\text{mol/L}$ using the CE-MS platform. Detection
9
10 269 sensitivity was significantly improved by DiLeu labeling with LODs ranging from 0.02 to 0.23
11
12 270 $\mu\text{mol/L}$ in CE-MS. The LC-MS platform showed even better detection sensitivity for DiLeu
13
14
15 271 labeled metabolites (LODs = 0.007 ~ 0.20 $\mu\text{mol/L}$). Because CE usually only loads a few nanoliter
16
17 272 of sample and is more sensitive to environmental fluctuation, the migration time of CE is not as
18
19
20 273 reproducible as the retention time of LC (Table 1). To ensure the reproducibility of CE,
21
22 274 background electrolyte was freshly made each day before analysis, and a sample containing a
23
24 275 mixture of free metabolite standards was used as quality control to monitor system performance
25
26
27 276 and stability each day before real sample analysis in CE-MS. An internal standard (3-
28
29 277 aminoquinoline, 1 μM , m/z 145.076, migration time 13.5 min) was also spiked into the sample for
30
31 278 the purpose of migration time correction, peak area normalization, and post-acquisition mass
32
33
34 279 calibration of CE-MS data.

35
36
37 280 The deuterium effect is known to affect the retention time of compounds in reversed phase
38
39 281 chromatography.^{31, 36, 46} Deuterium atoms are integrated in reporter groups (two deuterium atoms
40
41 282 in tag 116 and 117, and four deuterium atoms in tag 118) of 4-plex DiLeu reagents. To investigate
42
43 283 this potential retention time shift, SRM acquisitions were performed with 4-plex DiLeu labeled
44
45
46 284 metabolite standards in both CE-MS/MS and LC-MS/MS platforms. Because CE separation uses
47
48
49 285 open tubular columns and the interaction between the capillary surface and labeled compounds is
50
51 286 minimal, the deuterium effect is not observed with CE –MS platform. As expected, isobarically
52
53 287 labeled metabolites migrated at the exact same time in CE-MS/MS analysis (Fig. S3 A, B). The
54
55
56 288 extracted ion chromatograms of four tags showed negligible retention time differences in LC-

1
2
3 289 MS/MS analysis (Fig. S3 C, D), demonstrating the co-elution of isobarically labeled metabolite
4
5
6 290 and the consistency of reporter ion intensity ratios throughout the elution profile.
7
8

9 291 **Mouse urine metabolite identification and quantification**

10
11 292 Urine is an important biological fluid that has been used in diagnosing diseases for many years.²
12
13
14 293 ³ Endogenous metabolites in urine can reflect enzymatic activities, allowing for direct monitoring
15
16 294 of different biological states. Compared to other biofluids such as cerebrospinal fluid and serum,
17
18 295 urine collection is non-invasive, and the volume is less likely to be restricted. Here, urine samples
19
20 296 collected from four individual mice were prepared by 3 kDa molecular weight cut-off
21
22 297 ultracentrifugation to obtain urinary metabolite fractions, and utilized to validate DiLeu
23
24 298 derivatization and quantification of metabolites. The schematic workflow is illustrated in Fig. 5.
25
26
27
28

29 299 DiLeu labeling not only enables multiplexed quantitative analysis in one run, but also increases
30
31 300 the confidence of metabolite identification since DiLeu reagents only target primary and secondary
32
33 301 amine groups. In three top 5 DDA LC-MS/MS acquisitions of four labeled urine samples, more
34
35 302 than 500 MS/MS events were triggered, among which more than 300 MS/MS spectra contained
36
37 303 adequate DiLeu reporter ion intensities. Precursor masses that generated DiLeu reporter ions were
38
39 304 subtracted by 145.14 Da and searched against multiple online databases for identification including
40
41 305 Metlin,⁴⁷ Human Metabolome Database (HMDB),⁴⁸ and Madison Metabolomics Consortium
42
43 306 Database (MMCD).⁴⁹ Putative identification was achieved by accurate mass matching within 20
44
45 307 ppm. The presence of MS/MS reporter ions narrowed potential matches to primary and secondary
46
47 308 amine-containing metabolites from many potential hits in databases.
48
49
50
51
52

53 309 The analysis of labeled urine samples by both LC-ESI-MS/MS and CE-ESI-MS/MS platforms
54
55 310 offered cross validation and complementary coverage of urinary metabolites. A total of 40 amine-
56
57
58
59
60

1
2
3 311 containing metabolites were putatively identified and relatively quantified in mouse urine (Table
4
5 312 2). 35 labeled metabolites were detected in LC-MS/MS, 25 were detected in CE-MS/MS, and 20
6
7
8 313 metabolites were commonly shared between platforms. The base peak ion chromatogram of DiLeu
9
10 314 labeled mouse urine samples can be found in Fig. S4 (see supporting information). The relative
11
12 315 quantification of identified metabolites was accomplished by comparing the intensity ratio of
13
14 316 DiLeu reporter ions. Examples of MS/MS spectra are given in Fig. 6, representing the different
15
16 317 concentrations of metabolites from four individual mouse urine samples with good reproducibility
17
18 318 across three technical replicates. More examples of MS/MS spectra of labeled metabolites from
19
20 319 mouse urine samples can be found in Fig. S5 (see supporting information).
21
22
23
24
25 320
26
27

28 321 **Conclusions**

29
30
31 322 A qualitative and quantitative strategy for amine-containing metabolite analysis was established
32
33 323 based on 4-plex DiLeu labeling. Isobaric DiLeu labeling facilitated the accurate relative
34
35 324 quantification of amine-containing metabolites, improved the throughput of analysis, and
36
37 325 enhanced the electrospray ionization efficiency. Reversed phase LC separation efficiency and CE-
38
39 326 MS detection sensitivity of metabolites were greatly improved by DiLeu labeling. This approach
40
41 327 was also applied to the profiling and relative quantification of amine-containing metabolites in
42
43 328 mouse urine samples, using both nanoLC-ESI-MS/MS and CE-ESI-MS/MS platforms. We believe
44
45 329 that the MS-based DiLeu labeling will provide a useful tool for potential metabolic biomarker
46
47 330 discovery in the future.
48
49
50
51
52

53 331

56 332 **Acknowledgements**

1
2
3 333 The authors would like to thank Professor Paul Marker at the University of Wisconsin for
4
5
6 334 providing mouse urine samples and Professor David D.Y. Chen at the University of British
7
8 335 Columbia for generously providing the flow-through microvial interface unit of CE-ESI-MS. We
9
10 336 also thank Dustin Frost and Zhidan Liang in the Li Research Group for participating in the
11
12 337 synthesis of 4-plex DiLeu reagents. We thank Christopher Lietz and Qing Yu in the Li Group for
13
14
15 338 helpful discussions. This work was supported by National Institute of Health through Grants
16
17 339 1P20DK097826, R56 DK071801 and UW Graduate School IEDR Program.
18
19
20
21 340

22 341 **Notes**

23
24 342 Electronic Supplementary Information (ESI) is available.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


343 **References**

- 344 1. M. Mamas, W. B. Dunn, L. Neyses and R. Goodacre, *Arch Toxicol*, 2011, **85**, 5-17.
- 345 2. A. H. Zhang, H. Sun, P. Wang, Y. Han and X. J. Wang, *J Proteomics*, 2012, **75**, 1079-1088.
- 346 3. S. Ganti and R. H. Weiss, *Urol Oncol-Semin Ori*, 2011, **29**, 551-557.
- 347 4. M. Oresic, T. Hyotylainen, S. K. Herukka, M. Sysi-Aho, I. Mattila, T. Seppanan-Laakso, V. Julkunen,
348 P. V. Gopalacharyulu, M. Hallikainen, J. Koikkalainen, M. Kivipelto, S. Helisalmi, J. Lotjonen and H.
349 Soininen, *Transl Psychiat*, 2011, **1**.
- 350 5. E. Trushina, T. Dutta, X. M. T. Persson, M. M. Mielke and R. C. Petersen, *Plos One*, 2013, **8**.
- 351 6. A. Suppa, E. Lezzi, A. Conte, D. Belvisi, L. Marsili, N. Modugno, G. Fabbrini and A. Berardelli, *Cereb*
352 *Cortex*, 2010, **20**, 2224-2233.
- 353 7. S. G. Villas-Boas, S. Mas, M. Akesson, J. Smedsgaard and J. Nielsen, *Mass Spectrom Rev*, 2005, **24**,
354 613-646.
- 355 8. C. Sofie, H. Jerome, R. Jean-Michel, S. Piet and H. Niels, *J Neuroimmunol*, 2010, **228**, 37-37.
- 356 9. A. J. Alpert, *J Chromatogr*, 1990, **499**, 177-196.
- 357 10. D. J. Creek, A. Jankevics, R. Breitling, D. G. Watson, M. P. Barrett and K. E. V. Burgess, *Anal Chem*,
358 2011, **83**, 8703-8710.
- 359 11. J. M. Knee, T. Z. Rzezniczak, A. Barsch, K. Z. Guo and T. J. S. Merritt, *J Chromatogr B*, 2013, **936**,
360 63-73.
- 361 12. M. Piraud, C. Vianey-Saban, K. Petritis, C. Elfakir, J. P. Steghens and D. Bouchu, *Rapid Commun*
362 *Mass Sp*, 2005, **19**, 1587-1602.
- 363 13. S. S. Zhao, X. F. Zhong, C. Tie and D. D. Y. Chen, *Proteomics*, 2012, **12**, 2991-3012.
- 364 14. W. S. Kim, R. L. Dahlgren, L. L. Moroz and J. V. Sweedler, *Anal Chem*, 2002, **74**, 5614-5620.
- 365 15. P. Nemes, A. M. Knolhoff, S. S. Rubakhin and J. V. Sweedler, *Anal Chem*, 2011, **83**, 6810-6817.
- 366 16. P. Nemes, S. S. Rubakhin, J. T. Aerts and J. V. Sweedler, *Nat Protoc*, 2013, **8**, 783-799.
- 367 17. J. L. Edwards, C. N. Chisolm, J. G. Shackman and R. T. Kennedy, *J Chromatogr A*, 2006, **1106**, 80-
368 88.
- 369 18. N. L. Kuehnbaum and P. Britz-McKibbin, *Chem Rev*, 2013, **113**, 2437-2468.
- 370 19. M. D. Carter, M. W. Calcutt, B. A. Malow, K. L. Rose and D. L. Hachey, *J Mass Spectrom*, 2012, **47**,
371 277-285.
- 372 20. S. Pauwels, L. Antonio, I. Jans, A. Lintermans, P. Neven, F. Claessens, B. Decallonne, J. Billen, D.
373 Vanderschueren and P. Vermeersch, *Anal Bioanal Chem*, 2013, **405**, 8569-8577.
- 374 21. C. M. Slupsky, H. Steed, T. H. Wells, K. Dabbs, A. Schepansky, V. Capstick, W. Faught and M. B.
375 Sawyer, *Clin Cancer Res*, 2010, **16**, 5835-5841.
- 376 22. M. Sugimoto, D. T. Wong, A. Hirayama, T. Soga and M. Tomita, *Metabolomics*, 2010, **6**, 78-95.
- 377 23. K. Kim, S. L. Taylor, S. Ganti, L. N. Guo, M. V. Osier and R. H. Weiss, *Omics*, 2011, **15**, 293-303.
- 378 24. L. Lin, Z. Z. Huang, Y. Gao, Y. J. Chen, W. Hang, J. C. Xing and X. M. Yan, *Proteomics*, 2012, **12**, 2238-
379 2246.
- 380 25. M. A. Lorenz, M. A. El Azzouny, R. T. Kennedy and C. F. Burant, *J Biol Chem*, 2013, **288**, 10923-
381 10935.
- 382 26. W. C. Yang, F. E. Regnier, Q. Jiang and J. Adamec, *J Chromatogr A*, 2010, **1217**, 667-675.
- 383 27. M. R. Shortreed, S. M. Lamos, B. L. Frey, M. F. Phillips, M. Patel, P. J. Belshaw and L. M. Smith, *Anal*
384 *Chem*, 2006, **78**, 6398-6403.
- 385 28. K. Guo, F. Bamforth and L. Li, *J Am Soc Mass Spectrom*, 2011, **22**, 339-347.
- 386 29. K. Guo and L. Li, *Anal Chem*, 2009, **81**, 3919-3932.
- 387 30. J. L. Hsu, S. Y. Huang, N. H. Chow and S. H. Chen, *Anal Chem*, 2003, **75**, 6843-6852.

- 1
2
3 388 31. A. Thompson, J. Schafer, K. Kuhn, S. Kienle, J. Schwarz, G. Schmidt, T. Neumann and C. Hamon,
4 389 *Anal Chem*, 2003, **75**, 4942-4942.
5 390 32. J. P. Murphy, R. A. Everley, J. L. Coloff and S. P. Gygi, *Anal Chem*, 2014.
6 391 33. P. L. Ross, Y. L. N. Huang, J. N. Marchese, B. Williamson, K. Parker, S. Hattan, N. Khainovski, S. Pillai,
7 392 S. Dey, S. Daniels, S. Purkayastha, P. Juhasz, S. Martin, M. Bartlet-Jones, F. He, A. Jacobson and D.
8 393 J. Pappin, *Mol Cell Proteomics*, 2004, **3**, 1154-1169.
9 394 34. H. Kaspar, K. Dettmer, Q. Chan, S. Daniels, S. Nimkar, M. L. Daviglus, J. Stamler, P. Elliott and P. J.
10 395 Oefner, *J Chromatogr B*, 2009, **877**, 1838-1846.
11 396 35. L. M. Hui, F. Xiang, Y. Z. Zhang and L. J. Li, *Peptides*, 2012, **36**, 230-239.
12 397 36. F. Xiang, H. Ye, R. B. Chen, Q. Fu and L. J. Li, *Anal Chem*, 2010, **82**, 2817-2825.
13 398 37. J. H. Wang, Y. Z. Zhang, F. Xiang, Z. C. Zhang and L. J. Li, *J Chromatogr A*, 2010, **1217**, 4463-4470.
14 399 38. R. M. Sturm, C. B. Lietz and L. J. Li, *Rapid Commun Mass Sp*, 2014, **28**, 1051-1060.
15 400 39. E. J. Maxwell, X. F. Zhong, H. Zhang, N. van Zeijl and D. D. Y. Chen, *Electrophoresis*, 2010, **31**, 1130-
16 401 1137.
17 402 40. I. P. Shadforth, T. P. J. Dunkley, K. S. Lilley and C. Bessant, *Bmc Genomics*, 2005, **6**.
18 403 41. G. Theodoridis, H. G. Gika and I. D. Wilson, *Trac-Trend Anal Chem*, 2008, **27**, 251-260.
19 404 42. H. G. Gika, G. Theodoridis, J. Extance, A. M. Edge and I. D. Wilson, *J Chromatogr B*, 2008, **871**, 279-
20 405 287.
21 406 43. H. Pham-Tuan, L. Kaskavelis, C. A. Daykin and H. G. Janssen, *J Chromatogr B*, 2003, **789**, 283-301.
22 407 44. X. F. Zhong, E. J. Maxwell and D. D. Y. Chen, *Anal Chem*, 2011, **83**, 4916-4923.
23 408 45. H. Mirzaei and F. Regnier, *Anal Chem*, 2006, **78**, 4175-4183.
24 409 46. K. Guo, C. J. Ji and L. Li, *Anal Chem*, 2007, **79**, 8631-8638.
25 410 47. C. A. Smith, G. O'Maille, E. J. Want, C. Qin, S. A. Trauger, T. R. Brandon, D. E. Custodio, R. Abagyan
26 411 and G. Siuzdak, *Ther Drug Monit*, 2005, **27**, 747-751.
27 412 48. D. S. Wishart, T. Jewison, A. C. Guo, M. Wilson, C. Knox, Y. F. Liu, Y. Djoumbou, R. Mandal, F. Aziat,
28 413 E. Dong, S. Bouatra, I. Sinelnikov, D. Arndt, J. G. Xia, P. Liu, F. Yallou, T. Bjorn Dahl, R. Perez-Pineiro,
29 414 R. Eisner, F. Allen, V. Neveu, R. Greiner and A. Scalbert, *Nucleic Acids Res*, 2013, **41**, D801-D807.
30 415 49. Q. Cui, I. A. Lewis, A. D. Hegeman, M. E. Anderson, J. Li, C. F. Schulte, W. M. Westler, H. R. Eghbalnia,
31 416 M. R. Sussman and J. L. Markley, *Nat Biotechnol*, 2008, **26**, 162-164.
32
33
34
35
36
37 417
38
39
40 418
41
42
43 419
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

420 **Figures and Tables**

421



422

423 **Scheme 1** General structures of 4-plex DiLeu isobaric tag (A) and DiLeu labeled amine metabolite (B).

424 DiLeu reagent contains an isotopically coded reporter group, a balance group, and an amine reactive group

425 that targets the amine group of a metabolite. A new covalent bond can be formed at the amine group of a

426 metabolite during the labeling reaction.


427

428

429

430

431



432

433 **Fig. 1** Mass spectra of 12 DiLeu labeled (A) and unlabeled (B) metabolite standards mixture (5 μ M each),
 434 and MS/MS spectrum of DiLeu labeled norepinephrine (C). The 12 metabolites include alanine (Ala), γ -
 435 aminobutyric acid (GABA), valine (Val), leucine (Leu), dopamine (DA), histidine (His), norepinephrine
 436 (NE), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Trp), serotonin (5-HT), and lysine (Lys). CID
 437 collision energy for MS/MS fragmentation was 30 eV. The intensities of reporter ions (m/z 115.1, 116.1,
 438 117.1, 118.1) were used for relative quantification.

439

440

441

442




Fig. 2 Box plots of reporter ion ratios of DiLeu labeled metabolite standards at a theoretical 1:1:1:1 ratio (A) and a 1:5:2:10 ratio (B). Each box contains 36 data points from 12 metabolite standards with three replicates, obtained from direct infusion ESI-MS/MS analysis. Box denotes 25th and 75th percentiles; line within box denotes 50th percentile; whiskers denote standard deviation.





Fig. 3 Extracted ion chromatograms of 12 DiLeu labeled metabolite standards mixture (5 μ M each) in nanoRPLC-ESI-MS. Samples were dissolved in 10 μ L of 0.1% FA in H₂O and 3 μ L was loaded onto the nanoRPLC column.

473



474

475 **Fig. 4** Extracted ion electropherograms of 12 DiLeu labeled (dark grey) and unlabeled (red) metabolite
476 standards (5 μ M each) in CE-ESI-MS. Peak intensity of unlabeled Ala was enlarged by 10 fold in order to
477 be clearly seen in the figure.

478

479


480

481

482

483

484



487

488 **Fig. 5** Mouse urine analysis workflow. Urine samples were collected from four individual mice. Urinary
489 metabolites obtained from 3 kDa molecular weight cut-off ultracentrifugation were labeled separately with
490 4-plex DiLeu, combined, and purified prior to LC-MS/MS or CE-MS/MS analysis.

491

492

493


494

495

496

497

1
2
3 498
4
5
6 499
7
8
9 500
10
11
12 501
13
14
15 502
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560

Fig. 6 Examples of MS/MS spectra of DiLeu labeled metabolites from mouse urine samples showing the reporter ion region. 4-plex DiLeu labeled glycine (A, parent ion m/z 221.18) and histidine (B, parent ion m/z 301.22). Means and standard deviations of reporter ions from three replicates are shown in inserted tables.

512 **Table 1.** Reproducibility, linearity, and sensitivity of metabolites analysis in different platforms.

Compound	Label free metabolites in CE-MS			Labeled metabolites in CE-MS		Labeled metabolites in LC-MS		Relative quantification
	R ² (linearity) ^a	Migration time (min) ^b	LOD ^c (μmol/L)	Migration time (min) ^b	LOD ^c (μmol/L)	Retention time (min) ^b	LOD ^c (μmol/L)	R ² (linearity) ^d
Ala	0.9995	18.85 ± 0.21	1.24	17.50 ± 0.17	0.16	16.45 ± 0.02	0.11	0.9935
GABA	0.9998	14.12 ± 0.13	0.83	17.39 ± 0.17	0.11	16.95 ± 0.25	0.03	0.9185
Val	0.9981	19.85 ± 0.26	0.32	17.84 ± 0.12	0.04	17.03 ± 0.17	0.01	0.9999
Leu	0.9969	19.97 ± 0.25	0.43	17.95 ± 0.16	0.12	18.02 ± 0.03	0.03	0.9827
Lys	0.9990	15.70 ± 0.12	0.45	15.24 ± 0.17	0.06	18.56 ± 0.20	0.08	0.9977
DA	0.9926	15.03 ± 0.11	0.57	17.94 ± 0.25	0.21	17.34 ± 0.06	0.16	0.9975
His	0.9973	21.91 ± 0.33	0.36	14.45 ± 0.24	0.23	16.89 ± 0.25	0.20	0.9991
Phe	0.9995	16.32 ± 0.15	0.15	18.35 ± 0.19	0.02	18.41 ± 0.13	0.007	0.9997
NE	0.9970	15.83 ± 0.12	0.89	18.52 ± 0.17	0.10	16.80 ± 0.22	0.05	0.9916
5-HT	0.9933	22.33 ± 0.35	0.21	18.18 ± 0.18	0.09	18.96 ± 0.08	0.09	0.9963
Tyr	0.9975	21.32 ± 0.30	0.13	18.95 ± 0.22	0.05	17.15 ± 0.17	0.009	0.9999
Trp	0.9975	14.58 ± 0.16	0.20	18.70 ± 0.20	0.09	18.70 ± 0.17	0.01	0.9988

513 ^a R² for each label free metabolite was calculated from calibration curve at 0.5, 1, 5, 10, 20 μmol/L concentration.514 ^b average ± standard deviation (n = 6)515 ^c LOD = 3*SD (blank)/ slope516 ^d R² for relative quantification of each labeled metabolite was determined from intensity ratios of reporter ions in the 1:5:2:10 ratio labeling
517 experiment.

518

519 **Table 2.** Primary amine-containing metabolites that were labeled and putatively identified from mouse urine samples in LC-MS/MS and CE-MS/MS
 520 (top 5 DDA) platforms.


Compound	Formula	Molecular weight	Mass of labeled metabolite	LC-MS/MS		CE-MS/MS	
				Retention time (min)	Δ ppm	Migration time (min)	Δ ppm
Glycine	C2H5NO2	75.0320	221.1798	17.12	4.2	15.90	5.1
Putrescine	C4H12N2	88.1000	379.3883	18.57	-13.1	18.30	-12.6
Alanine	C3H7NO2	89.0477	235.1954	17.16	-4.4	17.61	-6.1
3-Aminoisobutanoate	C4H9NO2	103.0633	249.2111	17.55	8.1	—	—
Serine	C3H7NO3	105.0426	251.1903	17.22	-4.9	17.30	-6.9
Creatinine	C4H7N3O	113.0589	259.2067	17.81	12.9	16.72	7.5
Proline	C5H9NO2	115.0633	261.2111	17.87	-11.4	—	—
Valine	C5H11NO2	117.0790	263.2267	—	—	17.90	9.0
Threonine	C4H9NO3	119.0582	265.2060	16.73	2.7	18.46	9.8
Methylhistamine	C6H11N3	125.0953	271.2430	16.50	-0.5	—	—
Creatine	C4H9N3O2	131.0695	277.2172	17.88	6.4	19.10	6.0
Isoleucine/ Leucine	C6H13NO2	131.0946	277.2424	18.44	-5.7	17.92/18.01	-5.0
Asparagine	C4H8N2O3	132.0535	423.3417	19.19	-4.5	18.52	9.2
D-Ornithine	C5H12N2O2	132.0899	423.3781	19.78	-5.4	—	—
Aspartic acid	C4H7NO4	133.0375	279.1853	22.94	-7.0	18.70	-4.5
Guanidinobutyrate	C5H11N3O2	145.0851	291.2329	—	—	13.21	-9.5
Glutamine	C5H10N2O3	146.0691	292.2169	16.77	-2.4	18.32	10.6

Lysine	C6H14N2O2	146.1055	437.3937	17.78	10.6	—	—
Methionine	C5H11NO2S	149.0510	295.1988	17.95	3.4	—	—
Histidine	C6H9N3O2	155.0695	301.2172	16.45	10.2	—	—
Allantoin	C4H6N4O3	158.0440	304.1917	—	—	13.76	7.4
Aminoadipate	C6H11NO4	161.0688	307.2166	17.76	6.3	18.32	6.0
5-Hydroxylysine	C6H14N2O3	162.1004	453.3887	22.18	-9.2	20.21	-9.4
Pterin	C6H5N5O	163.0494	309.1972	17.76	9.8	14.56	9.2
Phenylalanine	C9H11NO2	165.0790	311.2267	19.74	5.7	—	—
3-Methoxytyramine	C9H13NO2	167.0946	313.2424	18.45	-0.6	—	—
N-Methyl-histidine	C7H11N3O2	169.0851	315.2329	16.46	7.1	—	—
Citrulline	C6H13N3O3	175.0957	466.3839	18.99	3.8	21.22	2.3
Hippuric acid	C9H9NO3	179.0582	325.2060	17.26	10.2	15.20	9.3
Tyrosine	C9H11NO3	181.0739	327.2216	17.70	1.4	18.79	3.8
Epinephrine	C9H13NO3	183.0895	329.2373	22.24	5.2	—	—
N-Acetylspermidine	C9H21N3O	187.1685	333.3162	—	—	20.12	8.1
Trimethyllysine	C9H20N2O2	188.1525	334.3002	20.39	-14.4	—	—
Aminohippuric acid	C9H10N2O3	194.0691	340.2169	—	—	14.16	4.7
4-Hydroxyhippurate	C9H9NO4	195.0532	341.2009	21.74	-0.1	—	—
Tryptophan	C11H12N2O2	204.0899	350.2376	18.96	7.4	15.19	14.8
N-acetyl-arginine	C8H16N4O3	216.1222	362.2700	17.68	-13.2	—	—
3-Nitrotyrosine	C9H10N2O5	226.0590	372.2067	22.78	0.5	22.23	-1.4
Carnosine	C9H14N4O3	226.1066	372.2543	20.03	-12.5	—	—

522

523 **Graphic Abstract**

524 The first demonstration of using 4-plex isobaric *N,N*-dimethyl-leucine (DiLeu) reagents for the
525 relative quantification of primary and secondary amine-containing metabolites.



526